Randomized pilot trial of βINF1a (Avonex) in patients with inclusion body myositis

Neurology

Volumn 57, Issue 9, 2001, Pages 1566-1570

  Tawil, R ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INCLUSION BODY MYOSITIS; MALE; MULTICENTER STUDY; MUSCLE MASS; MUSCLE STRENGTH; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0035856461     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.9.1566     Document Type: Article

References (45)

1. Prevalence of sporadic inclusion body myositis in Western Australia
2. Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: A study of 56 patients
3. Accumulation of deletions in human mitochondrial DNA during normal aging: Analysis by quantitative PCR
4. Nitric oxide induced oxidative stress in the muscle fibres of hereditary inclusion body myopathy and sporadic inclusion body myositis
5. Inclusion body myositis and myopathies
6. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments
7. Enhanced detection of Congo -red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer disease using fluorescence technique
8. Abnormal accumulations of prion protein mRNA in muscle fibers of patients with sporadic inclusion body myositis and hereditary inclusion body myopathy
9. Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain containing hyperphosphorylated tau
10. Sporadic inclusion body myositis: Counts of different types of abnormal fibers
11. Polymyositis and dermatomyositis
12. Immune effector mechanisms in inflammatory myopathies
13. Inclusion body myositis. Observations in 40 patients
14. Immune-mediated condition and antibodies associated with sporadic inclusion body myositis
15. Clonal restriction of T-cell receptor expression in infiltrating lymphocytes in inclusion body myositis persists over time
16. Idiopathic inflammatory myopathies: Inclusion body myositis, polymyositis, and dermatomyositis
17. Inclusion body myositis
18. Inclusion body myositis: Explanation for poor response to immunosuppressive therapy
19. Treatment of inclusion-body myositis and hereditary inclusion-body myopathy with reference to pathogenic mechanisms: Personal experience
20. Treatment of inclusion body myositis with IVIG: A double blind, placebo controlled study
21. Inclusion body myositis: Treatment with intravenous immunoglobulin
22. The interferons: Biological effects, mechanisms of action, and use in multiple sclerosis
23. Interferons: An overview of their pharmacology
24. Increased expression of b-chemokines in muscle of patients with inflammatory myopathies
25. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies
26. Intramuscular interferon 1a for disease progression in multiple sclerosis
27. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis
28. Results of the 3 year double-blind, placebo controlled study of interferon beta-1a (Rebif) in secondary progressive multiple sclerosis
29. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
30. Short form of depression inventory: Cross-validation
31. Facioscapulohumeral muscular dystrophy natural history study: Standardization of testing procedures and reliability of measurements
32. The natural history of motor neuron loss in amyotrophic lateral sclerosis
33. Measurement of isometric force in children with and without Duchenne muscular dystrophy
34. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): Implications for therapeutic trials
35. Clinical trial in Duchennes dystrophy. I. Design of the protocol
36. An open label trial of albuterol in facioscapulohumeral muscular dystrophy
37. Duchenne dystrophy: Randomized controlled trial of prednisone (18 months) and azathioprine (12 months)
38. Dual energy x-ray absorptiometry: Quantifying muscle mass in therapeutic trials
39. Body composition measurement by dual energy absorptiometry
40. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis
41. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection
42. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
43. Pharmacokinetics and pharmacodynamics of interferon beta-1a (IFN 1a) in healthy volunteers after intravenous, subcutaneous or intramuscular administration
44. Neopterin: A review
45. Interferon- β1a administration results in a transient increase of serum amyloid A protein and C-reactive protein: Comparison with other markers of inflammation